Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ed Gane

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
AIDS (London, England)|July 19, 2023
Reinfection incidence and risk among people treated for recent hepatitis C virus infectionMarianne Martinello, Joanne M Carson, Marc Van Der Valk, et al.
Hepatology International|July 24, 2015
Erratum to: Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 updateYun-Fan Liaw, Jia-Horng Kao, Teerha Piratvisuth, et al.
The New England Journal of Medicine|December 5, 2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis BPatrick Marcellin, E Jenny Heathcote, Maria Buti, et al.
Journal of Hepatology|June 8, 2023
Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: Results from randomized clinical trialsEd Gane, Young-Suk Lim, Jae B Kim, et al.
The New England Journal of Medicine|July 2, 2021
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin AmyloidosisJulian D Gillmore, Ed Gane, Jorg Taubel, et al.
The International Journal on Drug Policy|November 2, 2018
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapyJason Grebely, Brian Conway, Evan B Cunningham, et al.
The Lancet. Gastroenterology & Hepatology|January 10, 2018
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trialJason Grebely, Olav Dalgard, Brian Conway, et al.
Clinical and Translational Gastroenterology|October 23, 2020
Incidence, Factors, and Patient-Level Data for Spontaneous HBsAg Seroclearance: A Cohort Study of 11,264 PatientsYee Hui Yeo, Tai-Chung Tseng, Tetsuya Hosaka, et al.
Journal of Hepatology|August 29, 2025
Engineered monoclonal antibody tobevibart enhances HBsAg capture by Fc receptor-positive cells and activates HBV-specific T cellsLucia Vincenzetti, Rachel Wong, Roberta Marzi, et al.
Hepatology International|November 14, 2015
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 updateS K Sarin, M Kumar, G K Lau, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
AIDS (London, England)|July 19, 2023
Reinfection incidence and risk among people treated for recent hepatitis C virus infectionMarianne Martinello, Joanne M Carson, Marc Van Der Valk, et al.
Hepatology International|July 24, 2015
Erratum to: Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 updateYun-Fan Liaw, Jia-Horng Kao, Teerha Piratvisuth, et al.
The New England Journal of Medicine|December 5, 2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis BPatrick Marcellin, E Jenny Heathcote, Maria Buti, et al.
Journal of Hepatology|June 8, 2023
Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: Results from randomized clinical trialsEd Gane, Young-Suk Lim, Jae B Kim, et al.
The New England Journal of Medicine|July 2, 2021
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin AmyloidosisJulian D Gillmore, Ed Gane, Jorg Taubel, et al.
The International Journal on Drug Policy|November 2, 2018
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapyJason Grebely, Brian Conway, Evan B Cunningham, et al.
The Lancet. Gastroenterology & Hepatology|January 10, 2018
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trialJason Grebely, Olav Dalgard, Brian Conway, et al.
Clinical and Translational Gastroenterology|October 23, 2020
Incidence, Factors, and Patient-Level Data for Spontaneous HBsAg Seroclearance: A Cohort Study of 11,264 PatientsYee Hui Yeo, Tai-Chung Tseng, Tetsuya Hosaka, et al.
Journal of Hepatology|August 29, 2025
Engineered monoclonal antibody tobevibart enhances HBsAg capture by Fc receptor-positive cells and activates HBV-specific T cellsLucia Vincenzetti, Rachel Wong, Roberta Marzi, et al.
Hepatology International|November 14, 2015
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 updateS K Sarin, M Kumar, G K Lau, et al.
Pageof 8